digital-pathology
(12)
Gestalt Spent Eight Years Building the Boring Layer of Pathology - Now AI Has Somewhere Useful to Work
Most pathology AI companies sell the clever answer. Gestalt sells the place where the slide, the case, the pathologist and competing algorithms can finally meet - a workflow-first bet backed by a $7.5 million Series A.
Mayo Clinic Built a Medical Machine Around One Stubborn Rule
For more than 160 years, Mayo Clinic has organized medicine around the patient instead of the department. Now that old operating idea is becoming a global data, diagnostics and AI business - without abandoning the clinic at its center.
Qritive
Qritive is a Singapore-based healthtech company building AI-powered digital pathology software that helps pathologists detect, grade and classify cancer from whole-slide images. Its Pantheon platform digitizes the entire histopathology workflow, and a suite of hardware-agnostic AI modules - covering prostate, colon, breast, gastric, lymph node metastasis and immunohistochemistry - assist pathologists in reaching faster, more consistent diagnoses. The company sells to hospitals, pathology labs and pharmaceutical partners across Asia-Pacific, the US and the Middle East.
Virtue Diagnostics
Virtue Diagnostics is a platform-based in vitro diagnostics (IVD) company headquartered in Singapore, with manufacturing in Suzhou, China and clinical operations in Beijing. Founded in 2019, it develops affordable diagnostic instruments and reagents across chemiluminescence, clinical chemistry, hematology, clinical mass spectrometry, multiplex immunohistochemistry (mIHC) and molecular diagnostics, aiming to serve patients through every stage of disease - from early screening and diagnosis to treatment monitoring and minimal residual disease management. Its strategy centers on localized innovation and expansion in emerging markets including China, Singapore, Brazil, Indonesia and the Philippines. The company closed a US$100 million Series B round in January 2022 led by Sequoia China and Morningside Ventures.
Ataraxis AI
Ataraxis AI is a New York-based precision-oncology company building AI-native cancer diagnostics. Founded in 2022 by physician-scientist Jan Witowski and AI researcher Krzysztof Geras, it developed Kestrel, a digital-pathology foundation model trained on hundreds of millions of tissue images. Its flagship platform, Ataraxis Breast, reads standard pathology slides to predict recurrence risk and estimate whether an individual patient will benefit from chemotherapy - reported to be roughly 30% more accurate than the current standard of care - returning results within about an hour and without additional tissue procedures.
BostonGene
BostonGene is a Waltham, Massachusetts biotechnology company that applies AI-driven multiomics to cancer. Its Tumor Portrait platform integrates DNA and RNA sequencing with immune and tumor-microenvironment analysis into a single test, producing molecular profiles that help oncologists select therapies and help pharmaceutical partners design trials, identify biomarkers, and accelerate drug development. Founded in 2015 and led by CEO Andrew Feinberg, the company reached unicorn status in 2022.
Clarapath
Clarapath is a Hawthorne, New York medical robotics company that automates one of the most manual steps in cancer diagnosis: cutting and transferring paper-thin tissue sections onto slides for pathologists to read. Its flagship system, SectionStar, combines robotics, machine vision and AI to standardize tissue sectioning, cut turnaround times and ease chronic staffing shortages in histology labs. Founded in 2014 out of neuroanatomy research at Cold Spring Harbor Laboratory, the company has raised roughly $75 million and works with partners including the Mayo Clinic and Northwell Health.
Morphle Labs Inc.
Morphle Labs is a deep-tech healthcare automation company building robotic and AI-driven imaging systems for cancer diagnostics. Founded in 2017 and now operating between Bengaluru and New York, it combines robotics, optical engineering, and neural-network AI to automate the historically manual steps of histology - from tissue sectioning to whole-slide scanning to remote reporting. Its product line spans the RoboTome robotic microtome, the MorphoLens family of whole-slide scanners, and the HemoLens hematology scanners, giving pathology labs an end-to-end digital workflow at a fraction of the cost of legacy systems.
Valar Labs
Valar Labs is a Palo Alto precision-oncology company building AI tests that read the pathology slides already made during routine cancer care. Its Vesta platform applies proprietary foundation models to standard H&E-stained tissue images to predict how individual patients will respond to therapy - starting with bladder cancer, where it forecasts whether a patient is likely to benefit from BCG treatment and stratifies the risk of recurrence and progression. Founded in 2021 by Stanford AI researchers, the company has raised $26M total and earned the FDA's first Breakthrough Device Designation for an AI digital-pathology prognostic test in bladder cancer.
OptraHEALTH
OptraHEALTH is a San Jose-based AI healthcare intelligence company that turns dense genomic and clinical data into plain conversation. Its patented HealthFAX platform and GeneFAX product line use conversational AI, natural language processing, and knowledge graphs to help labs, hospitals, payors, and patients navigate genetic testing, revenue cycle management, prior authorization, and clinical decisions - letting people ask their health data questions through chat, mobile, and voice interfaces.
HistoWiz
HistoWiz is a New York-based histopathology company that turns tissue specimens into publication-quality digital slides in as little as three days. By pairing an automated, robot-driven lab with PathologyMap, a cloud platform hosting one of the world's largest preclinical pathology databases, it gives academic and biotech researchers fast, standardized histology plus AI analysis and access to board-certified pathologists - work that traditionally took weeks of slow, manual lab effort.
ArteraAI
ArteraAI is a precision medicine company building multimodal AI tests that personalize cancer therapy. Its flagship ArteraAI Prostate Test is the first AI-enabled predictive and prognostic biomarker recommended in the NCCN Guidelines for localized prostate cancer, validated across five Phase 3 trials.